CDK12 and neoplasm: In any case, because one allele of CDK12 was intact in the tumor, it appears unlikely that CDK12 alteration alone was important to the response to pembrolizumab, but additional study of clinical response to CPI in the setting of inactivation of one allele in CDK12 and the presence of dMMR is warranted.